SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention due to recent advancements in its pipeline, including significant progress in tecarfarin manufacturing and a collaboration with Abbott for its pivotal Phase 3 trial targeting LVAD patients. While some investors are optimistic about its potential in the anticoagulation market, community sentiment also highlights concerns around the company's cash position, recent offerings, and the notable presence of bot activity amplifying its trend.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is generating significant buzz following reports of a substantial planned investment from the US government, which includes an equity stake aimed at strengthening the domestic rare earth supply chain. This is further amplified by news of an upcoming rare earth metals and alloys production facility in France, bolstered by government support. The community is actively discussing the potential for a massive stock surge and a short squeeze, reflecting strong sentiment around the company's strategic importance in securing critical mineral resources.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC the metals company Inc. is trending after recent regulatory updates from NOAA allowed its US subsidiary to submit a consolidated application for an expanded deep-sea exploration and commercial recovery permit, streamlining the path to critical mineral production. The community is highly bullish, anticipating rapid permit approval and significant government backing due to national security implications and the urgent need for domestic supply of EV and low-carbon energy metals, with discussions frequently highlighting substantial upside and a potential short squeeze.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending following its mainnet migration to an EVM-compatible L2 on Arbitrum Orbit, positioning $JASMY as a custom gas token for AI and Web3 applications. This significant development has sparked intense debate, with many community members highlighting its foundational utility and regulatory backing in Japan as catalysts for a potential surge, while skeptics point to historical volatility and recent price action as typical 'pump and dump' behavior.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as intense debate erupts over a recent fatal shooting involving federal agents in Minneapolis. Community members are sharply divided, with some condemning the incident as an unjustified act against a citizen and others defending the agents' response to alleged interference with federal operations. This contentious event fuels broader discussions about federal authority and political polarization, potentially impacting ongoing government funding debates.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending amidst strong community excitement, primarily driven by rumors of a Coinbase listing and increasing institutional interest, with C2 Blockchain notably expanding its holdings. Enthusiasts are actively promoting it as the leading Bitcoin-native memecoin, emphasizing its fixed supply and decentralized nature as superior to other meme tokens and expressing high conviction for its long-term growth and potential to outperform.

Ethereum Classic

Ethereum Classic ($ETC) is trending with a mix of frustration over its lagging performance and fervent hope for an "alt season" rally. The community is actively debating its intrinsic value as a truly decentralized Proof-of-Work blockchain, with many long-term holders accumulating at current low levels. Optimism is fueled by anticipation of broader market catalysts like potential regulatory clarity and upcoming FED rate cuts, which could bring renewed institutional liquidity to the crypto sector.

The White Whale

WHITEWHALE is experiencing active community discussion around recent price volatility, with some attributing it to market manipulation and large-scale profit-taking. Despite this, a strong bullish sentiment persists, fueled by significant token burns, a substantial portion of supply locked long-term, and consistent growth in its holder base. The community largely views current dips as accumulation opportunities, reinforcing its belief in the token's long-term potential and legitimacy.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending due to recent market reports suggesting a potential shift in a major customer's assembly work, which many in the community are actively debating as a strategic play to acquire shares at a lower valuation. Despite this volatility, investors are highlighting the company's strong fundamentals and critical role in the expanding AI and data center infrastructure, with high anticipation for its upcoming earnings report to reaffirm its market leadership.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is actively discussed as a quantum computing leader following significant accumulation by institutional investors like BlackRock and its strategic advancement in government contracts. The company recently secured a $21.1 million Air Force project and joined the "Golden Dome" initiative, positioning itself as a full-stack quantum infrastructure provider, while its presence at CES 2026 highlights its commitment to commercial applications and ongoing community excitement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks Identifies Three...

<ul class="summary-bullets"><li>The company has now proposed an early-stage clinical trial to evaluate the cell therapy.</li><li>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</li><li>The company is also preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</li></ul><p>&nbsp;</p><p>Shares of Lunai Bioworks (LNAI) jumped 26% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy.</p><p>"We are seeing accelerating validation from both researchers and industry partners," <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models-302624947.html">said</a> CEO David Weinstein. He added that the early licensing activity reflects growing confidence in the platform's potential to unlock scalable treatments.</p><h2 class="st-heading-2">Data For Cell Therapy</h2><p>The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.</p><p>The company has now proposed an early-stage clinical trial to evaluate the cell therapy, manufactured from healthy donor cells and stored ready-to-use, across several high-risk tumors, including pancreatic cancer, which has a poor survival rate.</p><h2 class="st-heading-2">Plans Ahead</h2><p>Lunai is also advancing additional studies and expanding the clinical reach of its DCCT platform through collaborations with investigators in non-small cell lung cancer and prostate cancer.</p><p>Additionally, it is preparing for formal licensing negotiations and pursuing activities ahead of the commencement of human clinical trials in early 2026.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around LNAI jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down by 85% this year and by about 75% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-experimental-glp-1-drug-shows-weight-loss-blood-sugar-level-reduction-in-study/cL52hCvREXo">Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest 

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.

Equity

The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.


Top Biotech Stocks To Follow Now - November 5th

Danaher, Vertex Pharmaceuticals, Recursion Pharmaceuticals, Moderna, and Lunai Bioworks are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNAI News

LNAILunai Bioworks Inc.